SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Medicines " 100 found 🔀 AI-powered Shuffle
Sign in to save shuffle history.
World Humanitarian Day 2026: Protect those who protect humanity
19 August 2026, Cairo, Egypt – They treat the wounded. They deliver medicines across conflict lines. They keep hospitals running when electricity and water run low and essential supplies are disappearing. They respond...
Monitoring One Health action against antimicrobial resistance in Indonesia
Ministry of Health, with support from WHO and partners, convened a national multisectoral validation meeting for Indonesia’s 2026 TrACSS submission. Representatives from human health, animal health, fisheries, food and agriculture, environment, research institutions and development partners reviewed the country’s progress on AMR, and validated evidence supporting survey responses prior to submission. In the meeting, WHO presented Indonesia’s 2025 TrACSS results and facilitated technical sessions on the 2026 survey structure, rating principles and submission process.
PAHO Director’s Annual Report highlights health gains across the Americas despite growing challenges
Report highlights disease elimination milestones, progress in immunization and maternal health, and expanded access to medicines, while warning of the loss of the Region’s measles-free status and other health threats
Bristol Myers Squibb Building Life Science Industry’s Most Advanced AI Factory on NVIDIA Vera Rubin
The pharmaceutical company has demonstrated how AI can transform how drugs discovery and is now scaling AI across R&D to accelerate the discovery of next-generation medicines.
EMA and EISMEA boost cooperation to accelerate health innovations
Cooperation will encourage the development of innovative medicines and health solutions for patients
UK health regulator approves Novo Nordisk's weight-loss pill
Britain's medicines regulator approved Novo Nordisk's weight-loss pill on Thursday, giving patients a new needle-free treatment option and bolstering the Danish drugmaker's first-to-market lead against U.S. rival Eli Lilly .
Commentary: Native small business owner: Main Street needs someone in the room
I started Lakota Made in 2018 at my kitchen table with six salves, made from plant medicines I learned from Lakota elders. Today, we have a storefront on Riverfront Drive, a small production team, more than 100,000 online orders and customers in 213 countries and territories around the world. Our social media community has 179,000 […]
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif., March 16, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.
Brain-Targeted Drug Discovery Barriers Drive Deep Science Ventures and Medicines Discovery Catapult Deal
According to the World Health Organization’s Global Status Report on Neurology, over 40% of the global population is living with CNS diseases.
How scientists are trying to repair the body from within: Regenerative medicine and anti-aging
At Scripps Research and its drug discovery arm, the Calibr-Skaggs Institute for Innovative Medicines, scientists are developing regenerative medicine therapies designed to help the body repair itself from within. Unlike traditional medicines that primarily manage symptoms or slow disease progression, regenerative medicine aims to restore damaged tissues and rebuild function lost to aging and disease. Researchers are advancing programs focused on the heart, lungs, digestive tract and eyes, including investigational therapies for heart failure, idiopathic pulmonary fibrosis, inflammatory bowel disease, age-related macular degeneration and other chronic conditions that become more common as we age. Learn how scientists are activating the body’s natural repair mechanisms to explore a future where medicine may not only treat disease, but help reverse its damage.
Best Over-the-Counter Medicines and Health Products of 2026
U.S. News and World Report senior health editor Shanley Chien joins TODAY to exclusively reveal some of their picks for the best over-the-counter medicine and health products of 2026. Categories include first aid, gut health, hydration and energy, and more.
What Happens When Science Leads Us in an Unexpected Direction? - Revolution Medicines
What Happens When Science Leads Us in an Unexpected Direction? - Revolution Medicines / cancer, Jan Smith, OncoDaily, Oncology, Revolution Medicines
Wake County Commissioners to hear from WakeMed on potential merger with Atrium Health
WakeMed has defended the merger with Atrium Health, saying it would help reduce costs for supplies, medicines and equipment.
Rethinking discovery: how powerful screening tools are redefining the search for new medicines
In medicine discovery, identifying the right biological target has always been a critical and complex step. Today, the rise of powerful screening tools is fundamentally reshaping this process, creating a step-change in how we move from scientific hypotheses to transformative medicines. Advances in high-throughput screening, genomics and AI-driven analytics are enabling scientists to interrogate disease biology at unprecedented scale, bringing forward opportunities that were previously beyond reach.
Medicines watchdog to investigate UK peptide clinics over health claims
Exclusive: Guardian investigation finds several clinics making potentially unlawful claims about benefits of unregulated therapies
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release full year 2025 financial results and provide business updates on Wednesday, March 25, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET.
Turning coal to medicines: Chinese scientists bring a 160-year-old dream to life
Study cracks a puzzle that has baffled scientists and will reshape modern medicine production as the world reels from a global oil shortage.
Eli Lilly is reinventing the pharma business
The world’s largest drugmaker is betting big on preventive medicines—and learning from big tech
WHO reports measurable health impact in 2025 amid transition to new strategy
The World Health Organization (WHO) today released its Results Report, highlighting measurable improvements in people’s health worldwide in 2025, despite funding cuts affecting both the organization and the broader global health sector.
Countries race to provide oral health care for all in 100-Day Sprint across Asia
Twenty Asian countries and areas across the WHO Western Pacific and South-East Asia regions vowed to strengthen essential oral health benefits as part of a “100-Day Sprint” initiative, during the 16th Asian Chief Dental Officers Meeting held from 27 to 29 September in Kota Kinabalu, Malaysia. The meeting marked the midpoint of the 100-day sprint bolstering support for countries to develop essential oral health benefit packages that can be integrated into national universal health coverage plans. Convened by the two WHO regional offices and the Malaysian Ministry of Health as the Secretariat, the meeting brought together national oral health leaders from 20 Asian countries, staff from all levels of WHO, WHO collaborating centres and other development partners. Participating countries and areas included: Bangladesh, Bhutan, Brunei Darussalam, Cambodia, China, Hong Kong (SAR) China, India, Indonesia, Japan, Lao People’s Democratic Republic, Malaysia, Maldives, Mongolia, Nepal, the Philippines, Singapore, Sri Lanka, Thailand, Timor-Leste and Viet Nam. Participants reviewed progress and refined proposals using the WHO Service Package Delivery and Implementation (SPDI) Platform. Countries conducted bottleneck analyses across four key areas: service delivery, workforce, access to essential medicines and health products, and health financing. They identified practical actions to address implementation challenges and refined proposed revisions to their national oral health benefit packages. “There is no health without oral health. Through the 100-Day Sprint, countries are advancing the implementation of the Western Pacific regional implementation plan on oral health and strengthening progress towards universal health coverage,” noted WHO Regional Director for the Western Pacific Dr Saia Ma'u Piukala. Participants identified bottlenecks and proposed workable solutions to strengthen access to essential oral health care through primary health care, sharing experiences and discussing how best to translate policy commitments into feasible and sustainable action at the country level. Malaysian Minister of Health Datuk Seri Dr Dzulkefly Ahmad highlighted the importance of prevention and primary health-care approaches to improve oral health: “Oral diseases can have lifelong consequences, yet many are preventable. By integrating essential oral health care into primary health care and promoting prevention in schools and communities, we can improve oral health across the life course.”The WHO team led by Dr Huong Tran, Director of the Division of Health Promotion, Disease Prevention and Control of the WHO Western Pacific Region and national oral health leads from over 20 Asian countries visited the SK Pekan Putatan School, Sabah for school oral health programme including flouride mouth rinsing. © WHO / V. ChaudharyDr Huong Tran, Director of the Division of Health Promotion, Disease Prevention and Control for the WHO Western Pacific Region, emphasized key collaborative roles WHO can play. “Oral diseases are the most common noncommunicable diseases, yet many can be prevented and treated through essential oral health services delivered at the primary health-care level,” she said. “By sharing experiences and using WHO tools such as the SPDI Platform, countries are accelerating progress towards universal health coverage for oral health.” “Integrating oral health into broader health services is essential for reducing inequities, expanding access and recognizing oral health as an integral component of overall health and well-being. The 100-Day Sprint provides an important opportunity to translate this commitment into practical action and ensure that quality oral health services reach all people, especially those most in need,” said Dr Suman Rijal, Director of the WHO South-East Asia regional Department of Healthier Populations and Noncommunicable Diseases. As host of the meeting, Malaysia showcased ongoing efforts to strengthen oral health care through primary health care and prevention-focused approaches, while providing a platform for countries across the two WHO regions to exchange experiences and accelerate progress towards universal health coverage for oral health. “WHO is encouraged by Malaysia's leadership in addressing the burden of oral diseases and advancing universal health coverage for oral health through practical, country-led action,” said Dr Rabi Abeyasinghe, WHO Representative to Malaysia, Brunei Darussalam and Singapore. Countries will continue to refine and figure costs for national oral health benefits during the remaining sessions of the 100 days. These efforts support implementation of the WHO Global strategy and action plan on oral health 2023–2030, while also helping to expand access to essential oral health services through stronger and more equitable health systems across the WHO Western Pacific and South-East Asia regions.______________For more information, or to arrange media interviews, contact: WHO Regional Office for the Western Pacific: wprocom@who.int WHO Regional Office for South-East Asia: SEMediaRelations@who.int
Astronomical Aspirin And Interstellar Insulin: Are Space-Made Medicines The Future?
The long-anticipated manufacturing of medicines in microgravity has now been done twice at prototype scale, but is the cost and effort worth it?
Asia-Pacific parliamentarians urge bolder action for universal health coverage, climate resilience and responsible AI
Parliamentarians representing 16 countries from across the Asia-Pacific region concluded the Ninth Meeting of the Asia-Pacific Parliamentarian Forum on Global Health (APPFGH) today, reaffirming their key role in advancing universal health coverage (UHC) amid the risks and opportunities posed by AI and climate change. In adopting the Phnom Penh Communiqué, parliamentarians urged fellow legislators regionwide to strengthen sustainable financing for UHC to widen access to health for all, including the most vulnerable populations; promote responsible governance of AI amid ethical concerns over this fast-evolving technology; and build climate-resilient health systems to anticipate and respond to mounting pressures ranging from rising sea levels in coastal areas to air pollution and other environmental degradation.The National Assembly of Cambodia, with support from Cambodia’s Ministry of Health and the World Health Organization (WHO), hosted the Forum in Phnom Penh from 11 to 13 August 2026 – the first time the Forum has convened in a Mekong country.Parliamentarians urge action to close gaps in accessIn the Communiqué, parliamentarians recognized that at-risk and marginalized groups are the ones most severely affected by gaps in access to health services. These groups include people living in poverty, women and children, persons with disabilities, older people, migrants, refugees, and those in rural, remote or island communities. The Communiqué urges fellow parliamentarians and policy-makers to advocate for laws and policies that support sustainable financing to protect people from financial hardship, with a focus on primary health care, prevention and equity. "The Communiqué is a call to action. It sets out ambitious, concrete measures that deliver meaningful impact on the ground. We are all accountable for advancing universal health coverage and translating our commitments into tangible results. Cambodia is fully committed to advancing UHC, including the promotion of ‘healthy people, prosperous country’ campaign,” said Samdech Maha Rathsapheathika Thipadei Khuon Sudary, President of the National Assembly of the Kingdom of Cambodia.His Excellency Professor Chheang Ra, Minister of Health of the Kingdom of Cambodia, highlighted the need for collaboration beyond the health sector. “Universal health coverage cannot be achieved by the Ministry of Health alone. It requires support, particularly from parliamentarians, across political, legislative, financial, social protection, education, infrastructure, and environmental domains. While each country follows its own path, one factor is universally critical for success: strong governance and leadership. We all believe in this principle, and in our respective political roles, we remain committed to strengthening these key success factors to ensure that no one is left behind.”Promoting responsible AI adoption Parliamentarians acknowledged that, while AI has already demonstrated its ability to improve access to health services and support delivery, careful and ethical governance is necessary to safeguard quality, safety, privacy and public trust. This underscores the importance of parliamentarians in promoting legal and regulatory frameworks addressing liability, records ownership and data governance, while embracing innovation that protects ethical practice.“Without strong governance, safeguards for privacy and data security, sustainable financing, and attention to those most at risk of exclusion, new technologies may widen existing gaps instead of closing them. This is why parliamentarians matter. We pass laws. We approve budgets. We scrutinize government action. We represent communities. We can ask whether health services are reaching rural, remote, ageing, poor, and marginalized populations. We can ask whether innovation is being guided by equity, evidence, and ethics,” said Hon. Man Hee Lee, President of the Asia-Pacific Parliamentarian Forum on Global Health.Building climate-resilient health systemsParliamentarians also reiterated that the climate crisis is a direct threat to people’s health and to achieving UHC more broadly, deepening the same gaps in access already faced by at-risk and marginalized communities. They recognized the need for WHO Member States to ensure sufficient national appropriations and oversight, and for parliamentarians to raise awareness in their constituencies and mobilize local action in building climate-resilient and sustainable health systems.“Universal health coverage, climate change and AI cannot be addressed in isolation. The same communities struggling to access health services today are often the ones most exposed to climate shocks, and most in need of the opportunities AI can offer if this technology is governed responsibly,” said Dr Saia Ma’u Piukala, WHO Regional Director for the Western Pacific. “Having served previously in this Forum myself as a parliamentarian from Tonga, I recognize how the Phnom Penh Communiqué reflects the shared resolve of legislators across the Asia-Pacific region: the laws parliamentarians pass and the budgets they approve help ensure this progress reaches the people who need it most.”As the Forum drew to a close, delegates reflected on what they would carry back to their own parliaments and constituencies.“I wish to share three points here worth carrying home from Phnom Penh: we need to invest in primary health care as the foundation of coverage; we need to remove the barriers that keep people from care, whether financial, geographic or social; and we need to build systems that are inclusive by design, protecting those most at risk of being left behind,” added Hon. Ouch Borith, First Vice-President of the Senate of the Kingdom of Cambodia.###Notes for editors:The Asia-Pacific Parliamentarian Forum on Global Health (APPFGH) is a platform for parliamentarians to exchange ideas, build political will, strengthen capacity and foster collaboration towards sustainable health action. This was the ninth meeting of the APPFGH, with the theme “Universal Health Coverage in the era of Climate Change and Artificial Intelligence”. Target 3.8 of the Sustainable Development Goals calls on countries to achieve universal health coverage, including financial risk protection, access to quality essential health services, and access to safe, effective, quality and affordable essential medicines and vaccines for all. In the Western Pacific, UHC service coverage index (SDG 3.8.1) rose from 63 in 2000 to 81 in 2023 (figures include Indonesia), and roughly one in four people in the Western Pacific have experienced financial hardship (SDG 3.8.2). Progress towards UHC in the Asia-Pacific region remains uneven, with hundreds of millions of people still lacking access to essential health services or facing financial hardship due to health-related expenses. Strengthening the role of parliaments – through legislation, financing and oversight – is central to closing this gap and accelerating progress towards UHC across the region.Parliamentarians participating in APPFGH in Cambodia this week include: Hon. Pehin Dato Adanan YUSOF, Brunei Darussalam; Hon. Rosmawatty ABDUL MUMIN, Brunei Darussalam; Hon. LORK Kheng, Kingdom of Cambodia; Hon. YOS Phanita, Kingdom of Cambodia; Hon. KHOUN Khundy, Kingdom of Cambodia; Hon. HENG Halim, Kingdom of Cambodia; Hon. KHOENG Noupheap, Kingdom of Cambodia; Hon. SENG Nhak, Kingdom of Cambodia; Hon. LY Sukry, Kingdom of Cambodia; Hon. NHOEURN Raden, Kingdom of Cambodia; Hon. Dr Ratu Atonio LALABALAVU, Republic of Fiji; Hon. Vijay NATH, Republic of Fiji; Hon. Man Hee LEE, Republic of Korea; Hon. Dr Jiho CHA, Republic of Korea; Hon. Jonghun BAEK, Republic of Korea; Hon. Youngsuk SEO, Republic of Korea; Hon. Dr Phayvanh KEOPASEUTH, Lao People’s Democratic Republic; Hon. Suhaizan Bin KAIAT, Malaysia; Hon. Dr Perpetua KONMAN, Federated States of Micronesia; Hon. Ganmaa DAVAASAMBUU, Mongolia; Hon. Charmaine SCOTTY, Republic of Naoero; Hon. Vincent Ambance KUMURA, Papua New Guinea; Hon. Dr Edwin CRUZADO, Republic of the Philippines; Hon. AUUAPAAU Mulipola Aloitafua Mulipola, Samoa; Hon. ASIATA TAVUI Tafu Salevao, Samoa; Hon. Dr Alani Petelo TANGITAU, Tonga; Hon. Paul PAOLO, Republic of Vanuatu; Hon. Franklyn Ezra WILLIAM, Republic of Vanuatu.For more information, contact: WHO Regional Office for the Western Pacific: wprocom@who.int National Assembly of the Kingdom of Cambodia (International Relations Department): ir.nacambodia@gmail.com
16th Asian Chief Dental Officers Meeting: Advancing universal health coverage for oral health in the WHO Western Pacific and South-East Asia Regions
Session 3 of the 100-Day Sprint BackgroundOral diseases remain among the most prevalent noncommunicable diseases (NCDs) across Asia, affecting people throughout the life course and placing a significant burden on individuals, families and health systems. Countries across the World Health Organization (WHO) Western Pacific Region and South-East Asia Region have committed to strengthening oral health through regional action plans and by advancing universal health coverage (UHC). The 16th Asian Chief Dental Officers Meeting (ACDOM) serves as a regional platform for Chief Dental Officers in Asia to exchange experiences, strengthen collaboration and accelerate implementation of oral health commitments. For the first time, the meeting is being jointly organized by the WHO Regional Offices for South-East Asia and for the Western Pacific and the ACDOM Secretariat. This year's meeting introduces a 100-Day Sprint, bringing together oral health and UHC leads and technical experts to support countries in strengthening integration of oral health within national UHC benefit packages. Through the Sprint, participating countries will develop, refine, cost and operationalize country-specific essential oral health-care benefit packages using WHO tools, including the Service Package Delivery and Implementation (SPDI) Platform. The in-person 16th Asian Chief Dental Officers Meeting represents Session 3 and the midpoint of the 100-Day Sprint, providing an opportunity for countries to review progress, exchange experiences, identify challenges and refine their approaches before continuing with the remaining Sprint sessions. 100-Day SprintSession Date Format Title Session 1 (Day 0) 19 Aug Virtual Setting the Scene and Introducing Key Principles and Frameworks Session 2 16 SepVirtual Introduction to the SPDI Platform and Initial Mapping Exercise Session 3 27-29 Sep In-person, 16th Asian Chief Dental Officer Meeting, Malaysia Review and Refinement of Oral Health Service Packages Session 4 14 Oct Virtual Finalizing National Essential Oral Health Services Packages and Costing Exercise Session 5 (Day 100) 26 Nov Virtual Country Presentations and Closing of the 100-Day Sprint ObjectivesLeverage the 100-Day Sprint to define priority implementation actions for oral health in countries; Strengthen national capacity to design, cost and operationalize country-specific essential oral health care packages using SPDI platform; andExplore cross-country collaboration to expand access to essential oral health supplies and products, including harmonized specifications and pricing, and improve supply chains for essential dental preparations and medicines.Expected outcomesA draft country-specific essential oral health care benefit package developed using the SPDI platform and aligned with WHO’s Essential Oral Health Care packageA strengthened regional network in Asia of oral health and UHC leaders, fostering collaboration among South-East Asia and Western Pacific countries, WHO offices and WHO Collaborating Centres to support sustained implementation beyond the meetingParticipantsChief Dental Officers and national oral health programme leads;National focal points responsible for universal health coverage, health financing and health systems;Representatives from WHO country offices, regional offices and headquarters;WHO Collaborating Centres; andAcademic institutions and technical partners.
AI learns nature’s code: Allen Institute, UW and Fred Hutch launch $95M open science initiative
Three of Seattle's top scientific institutions are launching a nearly $95 million research initiative that will generate data and train AI models to design proteins and genes that don't exist in nature — sharing the results freely to help others develop new medicines and materials.
Two deadly flowers could inspire powerful new medicines
Scientists have figured out how two famously poisonous plants create chemicals with surprising medical potential. After tracking thousands of genes in wolfsbane and larkspur, they identified six enzymes needed to build a complex compound called atisinium. The team recreated the process inside tobacco plants, offering a sustainable way to produce and test these rare molecules in larger amounts.
EMA celebrates diversity and inclusion in science and healthcare
The EU body underlines its commitment to diverse perspectives in medicines regulation
Health Rounds: Common ADHD medicines help treat cancer-related fatigue
We also report on findings that help explain why the flu can be particularly dangerous for pregnant women and that open the door to potential future treatments.
Publication in Science charts a path to democratized molecular innovation
Blocc chemistry is a new way to make medicines, materials and a range of consumer products that is friendly to robots, AI and anyone. An international team of thought leaders has been assembled to prospectively map out how to keep this technology safe and maximize its potential benefits to society.
Specialties Honor Roll: Health Law
Health care is big business, and it’s constantly changing. New medicines and medical devices enter the market, regulations change and artificial intelligence is quickly changing the health care landscape. Ads for prescription drugs and health products are everywhere, while debates over access to care continue to make headlines. Behind all of it are legal issues. […]
Scientists finally crack nature's secret for building better cancer drugs
Researchers have cracked the code behind bacteria's ability to naturally manufacture multiple versions of powerful anti-cancer drugs. The discovery could make it much easier to engineer new cancer treatments inspired by nature, including improved versions of existing medicines.
Right medicine, right person: Jacintha Sivarajah on science with purpose
“All medicines have side effects, but it's just about trying to minimize the impact through providing the information patients and clinicians need or finding other ways to mitigate that impact.” — Jacintha Sivarajah
Women's health
The European Medicines Agency (EMA) works to ensure that the needs of women are considered throughout the development, evaluation and use of medicines in the European Union (EU). This includes promoting appropriate representation in clinical research, providing guidance to medicine developers, improving knowledge on medicine use during pregnancy and breastfeeding, and generating real world evidence on women's health.
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss medicines sold through the Hims platform.
A Life in Science: The role of data in advancing medicines
New in our A Life in Science series, we hear from Audrey Clapéron, Translational Biology Director, about the essential role of data in
Uganda closes its border with Congo, where suspected cases of rare Ebola type are surging
The measure, which goes against the guidance by the World Health Organization, underscores growing fears of contagion in East Africa from Bundibugyo, a rare type of the Ebola virus that is behind this outbreak and that has no approved medicines or vaccines.
WHO calls for action: “Together for health. Stand with science.” to mark World Health Day
The World Health Organization (WHO) today calls on people everywhere to renew their commitment to working together and supporting science as the twin engines driving better health, under the World Health Day 2026 theme: “Together for health. Stand with science.” The campaign marks the anniversary of WHO’s founding on 7 April 1948, launching a year-long public health campaign.
Ukraine: Critical health supplies destroyed in ongoing Russian attacks
Ongoing and deadly Russian attacks across Ukraine are causing serious healthcare disruption, with more than $1.5 million-worth of medicines and supplies destroyed in four separate strikes on warehouses used by the UN there since July.
Some people don’t lose weight with GLP-1s. Evidence is building that the drugs are helping anyway
The majority of people who start taking GLP-1 medicines with the hope of losing weight, the drugs can quiet cravings and help them shed stubborn pounds. But research is also continuing to reveal GLP-1 medicines’ benefits independent of weight loss — even if people gain weight.
Novo Nordisk Taps Anthropic’s Claude Science To Speed Up Drug Discovery — Here’s Everything Investors Need To Know
Novo will use Anthropic’s Claude Science in R&D to tackle scientific and drug discovery challenges, aiming to develop new medicines faster.
Health Rounds: Researchers find biomarker that could lead to improved schizophrenia treatments
Researchers have identified a biomarker linked to schizophrenia that could lead to new treatments to tackle symptoms of the debilitating mental disorder not addressed by current medicines.
A data-sharing clause derailed U.S.-Zimbabwe health talks. Now all funding ends this month
The withdrawal casts uncertainty over programs to combat HIV and other diseases in a country where shortages often force patients to bring basic supplies such as bandages to clinics and buy their own medicines.
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Positive results from the MULBERRY Phase III trial showed that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, demonstrated a statistically significant and clinically meaningful improvement in bone health in children (2 to
World Health Assembly endorses resolution on precision medicine
At the Seventy-ninth World Health Assembly, Member States endorsed a new resolution on Precision medicine: a path towards targeted, personalized and equitable care, taking an important step towards advancing precision medicine as part of efforts to strengthen equitable, effective and sustainable health systems. Precision medicine refers to the use of clinical, molecular, genomic and other health data to inform prevention, diagnosis and treatment, taking into account variability while applying appropriate ethical and legal safeguards. When integrated responsibly into health systems, precision approaches can improve outcomes across different disease areas and across the life course – from cancer and rare diseases to infectious diseases, maternal, newborn and child health, mental health and noncommunicable diseases. The resolution reflects rapid advances in genomics, diagnostics, data science and digital health, alongside widening global inequities in access to these innovations. Many populations – particularly in low- and middle-income countries – remain underrepresented in data and research, limiting the public health impact of precision medicine and risking the widening of health disparities if action is not taken now. "Precision medicine is not an aspirational idea for health delivery in the future – it is already transforming lives across the world. But its benefits remain out of reach for too many and the research driving progress is concentrated in high income countries. This WHA resolution gives global health leaders, ministries of health, and WHO a clear mandate: to act. From infant screening to setting up genomic databases WHO will work with countries to bring about the power of these innovations." Dr Meg Doherty, Director Science for HealthThrough the resolution, Member States commit to developing and strengthening national policies, infrastructure, workforce capacity and governance frameworks to support the safe, ethical and equitable integration of precision medicine into health systems, aligned with universal health coverage. This includes promoting affordability, ensuring inclusive research and data systems, strengthening regulation and data governance, and fostering collaboration across sectors and regions.WHO is requested to provide technical and normative support, review and coordinate existing guidance, facilitate global and regional collaboration, and develop a Global Strategy on Precision Medicine to guide equitable and context‑appropriate implementation. WHO stands ready to support Member States through tools such as a country maturity model for countries to self-assess capacity in implementing precision medicine depending on their context. In the immediate term WHO will map all existing guidance and frameworks and host extensive consultations with interest holders globally.By placing equity, inclusion and public value at the centre of precision medicine, the resolution reinforces WHO’s commitment to ensuring that scientific advances benefit all people, everywhere, and that no one is left behind in the next era of health innovation."By uniting people-centered healthcare with innovation, precision medicine has the potential to transform lives. This resolution helps ensure those advances serve the shared goal of health for all." Dr Sylvie Briand, Chief Scientist For further information please visit the Health Topic: Genomics
Global health leaders reaffirm commitment to Immunization Agenda 2030
During the Seventy-ninth World Health Assembly (WHA), held from 18 to 23 May 2026, Member States and global health partners reaffirmed commitment to the Immunization Agenda 2030 (IA2030), recognizing vaccines as one of the most powerful, cost-effective and equitable public health interventions.
When science advances, understanding must keep pace
We are living in an era of extraordinary scientific progress. We can target diseases in ways that were unimaginable a generation ago, develop increasingly sophisticated medicines and explore entirely new approaches to treatment.
Latvia pilots citizen engagement in research grant evaluations
Latvia has introduced an element of citizen engagement to the evaluation of nationally funded research grants. The aim is to both create more connections between science and society, and to improve the quality of its evaluations. The move comes as research funders across Europe are experimenting with ways to improve evaluation processes in the face of a sharpened focus on science’s impact on society. Evaluators of grant applications submitted to Latvia’s Fundamental and Applied Research Programme (FLPP), the country’s main research funder, will this year have the option of consulting citizen feedback on challenges the public thinks science should focus on to inform their decisions. “In recent years, both public discussions and policy-level debates in Latvia have highlighted the importance of demonstrating how publicly funded research contributes to society, the economy and the resolution of real-world challenges,” said a source at the Latvian Council of Science (LCS), which manages the FLPP. “At the same time, research institutions themselves expressed interest in improving the project evaluation framework while continuing to ensure that funding is awarded to the highest-quality projects,” the source added. The citizen input comes from a survey that was conducted between 25 February and 16 March 2025, to which 1,737 people responded. It gathered information on what the public views as problem areas for Latvia, and the role of science and technology in providing solutions to these problems. A summary of these responses has been included as an annex to the FLPP 2026 call for proposals that evaluators can refer to, purely in an advisory manner, when judging proposals. Results from the survey show that the main problem areas identified by the public were in healthcare and public health, followed by the development of new treatment methods and medicines, and then digital technology, data security and cyber security. At the bottom of the list was research aimed at acquiring new knowledge about the universe, matter and the laws of nature. Further analysis looked at the public view of the possible role of science in solving these problems. The survey charted 4,167 individual responses based on open-ended questions that were derived from the participants’ answers. The analysis again found that medical and health sciences topped the scoring, with 788 responses referring to the field. Humanities and the arts were bottom of the list, with 625. Digging further into the details, the survey suggests citizens are aware of and concerned about a number of research areas. This includes technologies and innovation to improve the environment or reduce pollution, the development of modern military technologies and cybersecurity tools, and the development and application of artificial intelligence, among others. “We hope this initiative will help strengthen public trust in science and create a more meaningful dialogue between researchers and society,” the LCS source said, adding that it offers benefits to researchers, evaluators and to the general public. More space for citizen engagement in evaluationsThere is a gradual but increasing use of citizen engagement in research evaluation processes around Europe, especially in healthcare, but it remains relatively rare, said Henry Sauermann, a professor at the European School of Management and Technology in Berlin and an expert in citizen science.“Given that we are at a point where citizen involvement is extremely limited, there is presumably space for more, but it's not that we should do it just because we want to do it,” he told Science|Business. He said some research lends itself better to having citizen input, and this usually tends to be on the applied end of the science spectrum where the public can offer useful feedback based on their experiences. He added that advising scientists on certain topics to study is also a useful approach, in the way that Latvia is doing. “The public does fund a lot of science, there's a lot of tax money going into this. We of course do want to preserve academic freedom, but it's also not unreasonable to incorporate more feedback or input from citizens where possible,” he said. Related articlesCitizen science: where, when, and how to let the public contribute to researchHow can Europe cope with a flood of AI-assisted research grant proposals?Data Corner: Horizon Europe’s AI, digital and data call success rate is 5.2%There are several ways of involving citizens in science funding. The most minimal way is having a few representatives on a panel, such as members of a patient group or union. The most direct way is crowdsourcing funding for specific projects. There is an increasing number of online platforms that allow the public to chip in to support scientific proposals.Sauermann studied this in a recent paper and found that it can have its uses, but it still is not clear if there are benefits to it. There are various assumptions linked to citizen engagement, for example that it increases public trust in science, or that it provides a representative view of what the public thinks about science. These are not necessarily true, Sauermann found. People who participate in engagement activities tend to already be very trusting of science, and, on the whole, it is generally the well-off and well educated who contribute, giving a narrow view of public opinion. On whether citizen input can help manage the increasing number of proposals that are being submitted due to assistance from AI, Sauermann is more sceptical. “The obvious answer to the flood of AI-written proposals is AI-driven evaluation,” he said, adding that it doesn’t mean citizen engagement shouldn’t be a part of evaluations in a well thought-out manner. Southern Denmark’s successful approachOne successful example of citizen engagement in science evaluations was implemented in southern Denmark. Between 2019 and 2025, citizens in the region were invited to vote to fund one of five pre-selected projects in the field of healthcare. The project, called A Healthier Southern Denmark, was a collaboration between regional authorities, the University of Southern Denmark, and two media partners. Over the seven years, there were 75,000 votes and significant public engagement online and on social media. “It was a bit of a wild project, we’d never done something like that before and we were a bit nervous about what would be said in the media about it. But actually, people were very positive,” said Anne Kathrine Overgaard, one of the main organisers of the project from the University of Southern Denmark. The university and its researchers have learned a lot from the experience, particularly about engaging with society and shaping their research to match real-world needs. This is important with Europe’s increasing focus on competitiveness and bringing innovations to market faster, Overgaard said. She hopes to see more citizen engagement in evaluation processes and in science more broadly. “For many years, citizen engagement has been a bit of an add-on to proposals, just to check a box. But I think things are changing,” she said. It’s less about citizens just gathering data and more “about the dialogue between the public and the scientists,” she said. The initiative ended last year as the team wanted to regroup to find fresh momentum. The development of AI and AI-written proposals has made Overgaard reflect on how the project could be reworked to help evaluators. She hopes to bring it back in the future. “It could be a good idea to try this initiative again in a slightly re-worked format,” she said.
Astronauts Could Grow Their Own Medicines in Space Using Plants
The pharmaceutical cabinet of the future might look a lot like a garden.
Protect patient access to life-saving drugs
By Leslie Herod Since its inception, Colorado’s Prescription Drug Affordability Board (PDAB) created fear among patients around effects to life-saving medicines and the negative ramifications price controls have on affordability. Five years on, those fears persist. Patients and advocates continue to push for protections for those facing the very likely scenario drugs whose price is […]
MPP Signs Multiple Regional Agreements To Expand Access To Flu Antiviral Medicine
The Medicines Patent Pool (MPP) has signed sublicense agreements with 11 manufacturers across multiple regions to expand access to generic baloxavir marboxil,
Novo Nordisk Taps Anthropic’s Claude Science To Speed Up Drug Discovery — Here’s Everything Investors Need To Know
Novo will use Anthropic’s Claude Science in R&D to tackle scientific and drug discovery challenges, aiming to develop new medicines faster.
Residents in rural Sudan say the Iran war has made it harder to get medicines
Some people in Sudan say they have struggled to obtain medicines, and the war in Iran has made that worse.
Firm Advises Oxford Science Enterprises on IP Matters Related Sensible’s $47 Million Financing
On October 6, 2026, Sensible Biotechnologies (Sensible), a biotechnology company developing a first-of-its-kind platform for naturally modified mRNA medicines, announced that it has secured $47…
The World Health Assembly adopts updated Global Action Plan on Antimicrobial Resistance (2026–2036)
Geneva, 23 May 2026 – Member States at the Seventy-ninth World Health Assembly (WHA79) adopted the updated Global action plan on antimicrobial resistance (GAP-AMR) 2026–2036, marking a major milestone in the global response to antimicrobial resistance (AMR) and delivering on a key commitment contained in the 2024 United Nations General Assembly Political Declaration on AMR. The updated plan was developed through a consultative process led by the Quadripartite organizations – FAO, UNEP, WHO and WOAH – with extensive engagement of Member States and stakeholders across sectors. AMR remains one of the most significant global health and development challenges, affecting humans, animals, plants, food systems and the environment. The updated GAP-AMR provides a comprehensive One Health framework to guide coordinated global, regional and national action over the next decade. It builds on the foundation established by the original GAP-AMR adopted by the World Health Assembly in 2015 while reflecting evolving evidence, lessons learned, and the commitments made at the 2024 UN High-Level Meeting on AMR. During the Assembly, Member States expressed broad support for the updated plan and its strengthened multisectoral and One Health approach. Delegates highlighted the importance of prevention-first interventions, including infection prevention and control, water, sanitation and hygiene (WASH), vaccination, biosecurity, and environmental measures. They also highlighted the need for responsible, equitable and sustainable use of antimicrobials, strengthened surveillance, innovation, and sustainable agrifood systems. The updated GAP-AMR is intended to serve as the global framework for coordinated action against AMR through 2036. It aims to accelerate global progress towards the commitments and targets agreed by Member States and support countries in developing, implementing and financing ambitious multisectoral national action plans. The plan also reinforces the importance of accountability, monitoring and reporting, sustainable financing, and international cooperation to address AMR through a One Health approach. The adoption of the updated GAP-AMR reflects renewed global commitment to preserving the effectiveness of antimicrobials and safeguarding advances in human, animal and plant health, food security, economic development and environmental sustainability. As implementation begins, continued collaboration among governments, international organizations, civil society, academia and the private sector will be critical to translating commitments into measurable impact. The Quadripartite organizations will continue supporting Member States and partners in operationalizing the updated GAP-AMR and advancing coordinated One Health action against AMR at country, regional and global levels.
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor (MCR) system, today announced financial results for its fiscal third quarter ended March 31, 2026, and provided a business update.
Luma locks down 15-year, $410M fund for life science investments
Luma Group today announced the final close of its inaugural life sciences venture capital fund, totaling $410 million. The New York-based investment firm has had a grip on life sciences since its founding in 2023. The funds unveiled today, dubbed LumaBio Fund I, include investments that have already been made into more than 10 biotechs. They include the likes of eye disease-focused Character Biosciences, rebranded Belgian biotech Coultreon Biopharma and cellular rejuvenation company Altos Labs. The fund saw early success when one of the companies it co-founded, called Vaccine Company, was picked up by Eli Lilly earlier this year for up to $1.55 billion. The acquisition of the in vivo nanoparticle technology-focused biotech formed part of a trio of vaccine buys for the Big Pharma, which has itself been on a prolonged spending spree in 2026. Luma's fund is structured as a 15-year investment with plans to support groundbreaking science and support companies through key milestones from discovery to commercialization, Luma explained in the release. "We founded Luma Group on the belief that extraordinary science, supported by patient, long-term capital, has the power to improve millions of lives," Joshua Fink, founder and managing member of Luma Group, said in the release. "This fund represents more than capital—it is a commitment to partnering with extraordinary innovators as they translate visionary science into life-changing medicines."
Cardinal Health lifts annual profit forecast on strong demand for specialty drugs
Drug distributor Cardinal Health on Thursday raised its 2026 profit forecast range, betting on strong demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.
UN and AU sign landmark agreement guaranteeing access to safe health products
The World Health Organization (WHO) and the African Medicines Agency (AMA) signed the Framework Agreement for Collaboration on Friday, which aims to strengthen regulatory systems and improve access to...
Universities Allied for Essential Medicines advocates for affordable health care
While a vial of insulin takes as little as $2 to manufacture, it can cost consumers $250 in the United States. Universities Allied for Essential Medicines, an international advocacy organization that has chapters at universities including UCLA, raised awareness about medication unaffordability during its annual North American conference at the Neuroscience Research Building from April 3 to 5.
FDA’s controversial vaccine chief will exit agency next month
The US Food and Drug Administration’s head of vaccines and biologic medicines will leave the agency at the end of April, a spokesperson confirmed to CNN on Friday.
Kyowa Hakko highlights Cognizin citicoline’s science-backed cognitive health benefits
Kyowa Hakko USA is spotlighting citicoline’s benefits for cognitive performance and long-term brain health through multiple complementary mechanisms. The supplier will exhibit its citicoline ingredient Cognizin at this week’s Complementary Medicines Australia (CMA) Innovation Day 2026 in Sydney, Australia (May 21). CMA Innovation Day is one of Australia’s annual industry gatherings for the nutraceuticals supply chain, showcasing the latest innovations shaping the market for vitamins, minerals, and supplements in Australia and the Asia-Pacific region.
Protective Gear, Essential Medicines Bound for DRC Health Providers Treating Ebola
Over the past week, Direct Relief has delivered 196 shipments of requested medical aid to 35 U.S. states and territories and 13 countries worldwide. The shipments contained 3.6 million defined dail…
Countries race to provide oral health care for all in 100-Day Sprint across Asia
Twenty Asian countries and areas across the WHO Western Pacific and South-East Asia regions vowed to strengthen essential oral health benefits as part of a “100-Day Sprint” initiative, during the 16th Asian Chief Dental Officers Meeting held from 27 to 29 September in Kota Kinabalu, Malaysia. The meeting marked the midpoint of the 100-day sprint bolstering support for countries to develop essential oral health benefit packages that can be integrated into national universal health coverage plans. Convened by the two WHO regional offices and the Malaysian Ministry of Health as the Secretariat, the meeting brought together national oral health leaders from 20 Asian countries, staff from all levels of WHO, WHO collaborating centres and other development partners. Participating countries and areas included: Bangladesh, Bhutan, Brunei Darussalam, Cambodia, China, Hong Kong (SAR) China, India, Indonesia, Japan, Lao People’s Democratic Republic, Malaysia, Maldives, Mongolia, Nepal, the Philippines, Singapore, Sri Lanka, Thailand, Timor-Leste and Viet Nam. Participants reviewed progress and refined proposals using the WHO Service Package Delivery and Implementation (SPDI) Platform. Countries conducted bottleneck analyses across four key areas: service delivery, workforce, access to essential medicines and health products, and health financing. They identified practical actions to address implementation challenges and refined proposed revisions to their national oral health benefit packages. “There is no health without oral health. Through the 100-Day Sprint, countries are advancing the implementation of the Western Pacific regional implementation plan on oral health and strengthening progress towards universal health coverage,” noted WHO Regional Director for the Western Pacific Dr Saia Ma'u Piukala. Participants identified bottlenecks and proposed workable solutions to strengthen access to essential oral health care through primary health care, sharing experiences and discussing how best to translate policy commitments into feasible and sustainable action at the country level. Malaysian Minister of Health Datuk Seri Dr Dzulkefly Ahmad highlighted the importance of prevention and primary health-care approaches to improve oral health: “Oral diseases can have lifelong consequences, yet many are preventable. By integrating essential oral health care into primary health care and promoting prevention in schools and communities, we can improve oral health across the life course.”The WHO team led by Dr Huong Tran, Director of the Division of Health Promotion, Disease Prevention and Control of the WHO Western Pacific Region and national oral health leads from over 20 Asian countries visited the SK Pekan Putatan School, Sabah for school oral health programme including flouride mouth rinsing. © WHO / V. ChaudharyDr Huong Tran, Director of the Division of Health Promotion, Disease Prevention and Control for the WHO Western Pacific Region, emphasized key collaborative roles WHO can play. “Oral diseases are the most common noncommunicable diseases, yet many can be prevented and treated through essential oral health services delivered at the primary health-care level,” she said. “By sharing experiences and using WHO tools such as the SPDI Platform, countries are accelerating progress towards universal health coverage for oral health.” “Integrating oral health into broader health services is essential for reducing inequities, expanding access and recognizing oral health as an integral component of overall health and well-being. The 100-Day Sprint provides an important opportunity to translate this commitment into practical action and ensure that quality oral health services reach all people, especially those most in need,” said Dr Suman Rijal, Director of the WHO South-East Asia regional Department of Healthier Populations and Noncommunicable Diseases. As host of the meeting, Malaysia showcased ongoing efforts to strengthen oral health care through primary health care and prevention-focused approaches, while providing a platform for countries across the two WHO regions to exchange experiences and accelerate progress towards universal health coverage for oral health. “WHO is encouraged by Malaysia's leadership in addressing the burden of oral diseases and advancing universal health coverage for oral health through practical, country-led action,” said Dr Rabi Abeyasinghe, WHO Representative to Malaysia, Brunei Darussalam and Singapore. Countries will continue to refine and figure costs for national oral health benefits during the remaining sessions of the 100 days. These efforts support implementation of the WHO Global strategy and action plan on oral health 2023–2030, while also helping to expand access to essential oral health services through stronger and more equitable health systems across the WHO Western Pacific and South-East Asia regions.______________For more information, or to arrange media interviews, contact: WHO Regional Office for the Western Pacific: wprocom@who.int WHO Regional Office for South-East Asia: SEMediaRelations@who.int
Chargé Arnold Speech - Implementation Plan of Five-Year Health MOU - U.S. Embassy in Madagascar
Chargée d’Affaires Stephanie Arnold's Speech Discussion on the implementation plan for the five-year health Memorandum of Understanding (…) Colleagues, and honored guests, Good morning, and welcome to the United States Embassy. It is a pleasure to host you today for the second day of this important workshop to discuss the implementation of our bilateral health Memorandum of Understanding on U.S. Government health activities in Madagascar, made possible through the Trump Administration’s America First Global Health Strategy. Today’s focus— discussing a shared vision and developing a preliminary draft for the health MOU Implementation Plan and the terms of reference for the two committees that will steer its implementation—is a decisive step in moving from commitments on paper to concrete action over the next five years. On December 22, 2025, the Governments of Madagascar and the United States signed a five-year bilateral health MOU, with a financial intention of approximately 554 billion Ariary from the United States and This jointly decided MOU intends to strengthen Madagascar’s health system, support lifesaving services, and improve disease prevention and response that matter to both our countries’ health security. For the United States, this means detecting and containing infectious disease outbreaks including malaria, polio, and emerging health threats before they can reach American shores through international travel and trade, protecting American families while reducing the need for costly domestic emergency responses Yesterday, technical experts from the Ministry of Public Health and the U.S. Government worked in thematic groups to draft a preliminary Implementation Plan. Today, your task is to review the shared vision and preliminary draft MOU implementation plan, and the proposed terms of reference for the Joint Steering Committee and the Operational Committee that will guide its implementation. These committees are not just administrative structures. They are the mechanisms that will ensure clear roles and responsibilities, regular dialogue between our two governments, consistent monitoring of progress, and real accountability for the results that will directly benefit the lives of Malagasy citizens. They will also track performance against the benchmarks we have jointly established, which will guide the continuation of U.S. support over the five-year period . Continued U.S. support will be contingent on meeting these performance benchmarks. This ensures accountability to both American and Malagasy taxpayers and guarantees that our partnership delivers measurable results. America First Foreign Assistance means that U.S. support must be strategic, results-driven, and accountable to our taxpayers. It also means we aim to support greater self-reliance and reduced long-term dependence on foreign assistance, with systems that are increasingly financed and led by Madagascar itself. This approach benefits both our nations: Madagascar gains sustainable health capacity, while the United States advances our health security interests and creates opportunities for American health innovations and companies to support Madagascar’s development. In that spirit, I want to recognize the presence of the Ministry’s leadership and the technical directors and program heads responsible for surveillance, basic health services, family health, immunization, countering malaria, laboratories, medicines, and health information systems. Your leadership and technical expertise are essential if this bilateral health MOU is to translate into real and lasting improvements for people in need across the country. Let me emphasize how important collaboration is to the United States in this effort. We can bring American resources, technical expertise, and tools. But this bilateral health MOU can only succeed if it reflects Madagascar’s priorities and if Malagasy institutions lead and maintain its implementation. We see this not as a U.S. project, but as a joint framework under Malagasy leadership, with U.S. support. That is why we are genuinely pleased to host this event here at the Embassy. Opening our doors to you today symbolizes our commitment to work side by side and to remain transparent about how we use U.S. resources in support of Madagascar’s health system. In closing, thank you for your time and your partnership. We are very happy to welcome you here and proud to accompany Madagascar in this next step of implementation planning for our bilateral health MOU. I wish you a productive and focused session. The work you do today will shape how our two governments cooperate on health in the years ahead; it will influence the quality and reliability of health services that Malagasy communities receive; and, most importantly, it will help protect both our nations from infectious disease threats while building Madagascar’s capacity for long-term health system sustainability. Thank you.
GSK and Amgen to add medicines to TrumpRx, Fox Business reports
GSK and Amgen will add their medicines to TrumpRX, the prescription drug website launched by President Donald Trump's administration, Fox Business reported on Friday.
We're 'green chemists'—why we think this emerging science can transform the way the world uses its resources
Society depends on chemistry far more than we consciously realize, from medicines to energy to electronics. However, chemistry is viewed with as much apprehension as gratitude, because of the pollution ...
Pharmaceutical innovation: a strategic investment in health and growth
Governments around the world are confronting increasingly common challenges: how to drive economic growth, address demographic changes and productivity pressures, and how to strengthen national resilience. Investment in health is fundamental to achieving these goals, and medicines and vaccines are central to this effort. We are at the cusp of the next golden age in...
Particle Engineering Takes Center Stage as Pharma Formulation Science Pushes Toward the Clinic
A forthcoming special issue of the Journal of Pharmaceutical Investigation will spotlight how particle engineering and formulation science are turning poorly soluble drug candidates into manufacturable medicines.
Stomach-turning sexually transmitted infection is on the rise — and standard medicines are failing
Shigella bacteria are becoming harder to treat as drug-resistant strains rise, and doctors warn Americans should be concerned but not panicked.
Obesity Drug Prices Undercut Healthcare Savings, CVS CEO Says
CVS Health Corp. Chief Executive Officer David Joyner said that drugmakers must significantly reduce the price of anti-obesity medicines before the drugs will save money for commercial health insurance plans.
EMA steps up efforts on medicines for women’s health
Initiatives to map gaps, challenges and prioritise further actions
Generic, Biosimilar Medicines Saved US Health Care $496B in 2025
The Association for Accessible Medicines report, prepared with the IQVIA Institute, also reports $25.4 billion in biosimilar savings for the year.
Biogen Beats Estimates as New Medicines Overtake MS Business
Biogen Inc. reported quarterly revenue and adjusted earnings that beat analysts’ expectations as sales of newly acquired kidney and eye-disease drugs helped offset declining revenue from multiple sclerosis medicines.
Flagship Pioneering and Lean Business Services Company Announce Collaboration to Advance Healthcare Innovation and AI-Enabled Biomedical Research in Saudi Arabia
/PRNewswire/ -- Flagship Pioneering, the scientific innovation company behind Moderna, Generate Biomedicines, and more than 100 other life sciences ventures,...
Safety fears as scientists make first viruses designed by AI
Researchers say breakthrough offers hope for new medicines but also raises urgent biosecurity questions
New global guidelines warn against obesity drugs for children under 10
Care should focus on healthy eating and exercise, not medicines such as weight-loss injections, says the World Health Organization
FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double
Revolution Medicines' Rasonque targets the RAS protein driving 95% of pancreatic adenocarcinoma cases, offering a critical option after chemotherapy fails.
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif., May 13, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended March 31, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates.
Sunlight Boosts Fertility? What Scientists Have Discovered Will Surprise You - Futura-Sciences
Vitamin D, Sunlight, and Sperm: Digging Into the Science A meta-analysis published in the journal Biomedicines reviewed several observational studies that all pointed to a significant link between vitamin D levels—which are mainly produced in humans through sunlight exposure—and sperm characteristics. These studies also suggested a connection between higher blood...
Lilly’s GLP-1 Windfall to Fund Investments in Women’s Health
The pharmaceutical giant has been assembling experts and hunting for new medicines across conditions including bone health and endometriosis, sources told Bloomberg.
Precigen Reports First Quarter 2026 Financial Results and Business Updates
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced first quarter 2026 financial results and business updates.
PAHO regional meeting of health ministers concludes with new measures to strengthen health security and address key health threats
Health authorities approved new regional strategies to strengthen preparedness for health emergencies, tackle antimicrobial resistance, curb dengue and other arboviral diseases, and improve food safety, while advancing access to vaccines, medicines and other essential health technologies across the Americas.
7 ways AI is advancing healthcare and wellbeing around the world
AI-powered tools are being used to bring greater efficiency and security to healthcare around the world and increase access to medicines and care.
Hims & Hers Health and Novo Nordisk End Lawsuit Over Weight Loss Medications, Enter Collaboration
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss medicines sold through the Hims platform. Shares of Hims & Hers Health Inc. jumped more than 40% in ...
Germany pushes through healthcare reform package despite pharma's drug discount resistance
Even as the effort has met with fierce pushback from drugmakers, trade groups and opposition parties in the country’s own government, German lawmakers late Friday voted to pass health insurance ref | Even as the effort has met with fierce pushback, German lawmakers late Friday voted to pass health insurance reforms aiming to cut healthcare costs, in part by hiking up mandatory rebates that pharmas must pay on branded medicines.
Mozambique strengthens regulation of medicines and imported vaccines, boosting health protection
Mozambique has reached a major milestone in strengthening the regulation of medicines and imported vaccines, with its national regulatory authority recognized by the World Health Organization (WHO) as having a stable, well-functioning and integrated regulatory system.The Autoridade Nacional Reguladora de Medicamentos de Moçambique (ANARME) has achieved Maturity Level 3 (ML3) for the regulation of medicines and imported vaccines under WHO’s global classification of national regulatory authorities.Mozambique becomes the 10th country in Africa to reach ML3, joining Egypt, Ethiopia, Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania and Zimbabwe and marking further momentum in strengthening regulatory systems across the region.For people in Mozambique, stronger regulation means greater assurance that medicines and vaccines are appropriately evaluated for quality, safety and efficacy and monitored throughout their lifecycle. It also strengthens the country’s ability to identify and respond to safety concerns and substandard or falsified products, while supporting timely access to quality-assured health products.“Mozambique’s achievement is the result of sustained investment in regulatory capacity that will deliver crucial benefits for public health,” said Dr Sylvie Briand, WHO Chief Scientist and Assistant Director-General a.i. for Health Systems, Access and Data. “Strong regulatory systems protect people, build confidence in health products and help countries respond more effectively to evolving public health needs and challenges. Mozambique’s progress also contributes to advancing regulatory capacity across Africa and promoting more equitable access to safe and quality-assured medicines and vaccines.”Building a stronger regulatory systemMozambique’s achievement follows years of sustained efforts to build the institutions and capabilities needed for effective regulation.WHO worked closely with ANARME throughout this process, assessing the national regulatory system and supporting the authority in addressing identified gaps and strengthening priority areas.WHO evaluates national regulatory systems using its Global Benchmarking Tool (GBT), which assesses the regulatory functions required to ensure the quality, safety and efficacy of medical products. These include registration and marketing authorization, licensing, market surveillance and control, pharmacovigilance, regulatory inspection, laboratory testing and oversight of clinical trials, as applicable. WHO’s maturity levels range from 1 to 4. Reaching ML3 confirms a stable, well-functioning and integrated regulatory system, while ML4 represents an advanced system focused on continuous improvement.Benefits for Mozambique and the African continentAn ML3 regulatory system can support more timely and predictable regulatory decisions, reinforce safety monitoring and help ensure that health products entering and remaining on the market meet appropriate standards.It also creates greater opportunities for regulatory cooperation and reliance – approaches that help authorities make use of the work and decisions of trusted regulators, reduce unnecessary duplication and allocate limited resources more efficiently, while maintaining rigorous standards for quality, safety and efficacy.As the first Portuguese-speaking country in Africa to reach ML3, Mozambique’s experience can also contribute to strengthening regulatory systems and fostering greater cooperation, knowledge sharing and reliance among Portuguese-speaking countries and across the African continent. Its achievement further reinforces a more connected African regulatory ecosystem, providing a solid foundation on which the newly established African Medicines Agency can build to advance regulatory convergence and cooperation across the region.Strengthening confidence in regulatory recognitionMozambique’s achievement comes as WHO strengthens the process through which the performance of national regulatory systems is recognized.The newly established Technical Advisory Group on Regulatory Systems Strengthening (TAG-RSS) brings together independent international experts to advise WHO on whether recommendations concerning regulatory authorities reaching ML3 and ML4 and WHO-Listed Authorities, are supported by the findings of WHO evaluation processes. Its recommendations provide an additional level of independent assurance, strengthening the impartiality, transparency and credibility of WHO’s recognition process.Mozambique is among the first countries to achieve ML3 following consideration and recommendation by the TAG-RSS. As part of the same TAG-RSS process, South Africa was recommended to retain its ML3 status for the regulation of vaccines manufactured, imported or distributed in the country, following an additional WHO assessment. This extends the recognition first granted in 2022 and underscores the sustained performance of the South African Health Products Regulatory Authority (SAHPRA).The two recognitions highlight continued progress in strengthening regulatory systems across Africa, as well as the importance of continued performance, improvement and assessment in sustaining regulatory maturity.WHO will continue working with ANARME and SAHPRA to sustain these gains and support continuous improvement as science, technologies and public health needs evolve.
The Science Of Vitamin Patches: Do They Work And Are They Worth Your Money?
Some medicines can be successfully delivered by skin patch. Quite a lot can’t.
Is Pfizer's New Business Big Enough To Carry The Old One?
Pfizer (PFE) trades at about 95% of its 52-week high. The business that has to justify that price, the medicines it has launched and acquired, is still only about a fifth of the company. The stock returned roughly 24% over the past year against about 17% for the S&P 500, so investors have so far given the handoff the benefit of the doubt. It is a large bet on a small slice.
Traditional Medicine Innovation for Health Impact: Financing, Collaboration, and Future Pathways
This session brings together WHO, Member States, innovators, regulators and private sector partners to explore the role of integrating and advancing traditional medicine to improve health outcomes, while accelerating innovation, partnerships and collaboration. Discussions will focus on translating evidence and innovation into implementation, addressing financing and policy barriers, and identifying practical pathways to scale credible, community-rooted traditional medicine approaches to expand access, equity and health impact.Watch live on YouTube
EMA welcomes political agreement on Critical Medicines Act | European Medicines Agency (EMA)
Act to improve availability, production and supply of critical medicines in the European Union
Why Priyanka Gandhi’s ‘gaumutra expert’ remark should concern anyone who values science
Throughout history, many medicines originated from traditional knowledge. Aspirin traces its origins to willow bark. Artemisinin emerged from traditional Chinese medicine.
WHO calls for action: “Together for health. Stand with science.” to mark World Health Day
The World Health Organization (WHO) today calls on people everywhere to renew their commitment to working together and supporting science as the twin engines driving better health, under the World Health Day 2026 theme: “Together for health. Stand with science.” The campaign marks the anniversary of WHO’s founding on 7 April 1948, launching a year-long public health campaign.
Situation Report No.11: Earthquakes in Venezuela 2026 (M7.2 and M7.5)
Nearly three months after the 24 June 2026 earthquakes in Venezuela, the response has moved into early recovery while sustaining essential emergency operations. Efforts now center on maintaining continuity of care across mental health, sexual and reproductive health, maternal and neonatal care, NCDs, and rehabilitation, alongside restoring affected facilities, supporting transitional camps, and strengthening Health Cluster coordination as Emergency Medical Teams and international partners withdraw. Health system recovery is advancing, with 16 ASICs and 356 health facilities assessed (61% operational) and rehabilitation progressing under CERF, CFE and US funding, while fluctuating electricity, medication refrigeration and emergency-generator gaps continue to challenge the safe continuity of essential health services. Public health surveillance and prevention remain active, with 47,145 cumulative vaccine doses administered and 556 health professionals trained, while intensified surveillance in La Guaira and Miranda and mounting environmental risks from tropical rains and heatwaves continue to require sustained vector-control and water/sanitation action. Contraception remains the most consistent unmet need across assessed shelters, particularly among adolescents and young women, while mental health needs continue to rise across the transitional camps amid limited supplies and specialized personnel. PAHO/WHO continues to support the response with critically needed medical supplies and medicines, having shipped 46.6 metric tons to Venezuela to date, benefiting 72 actors and reaching 117,714 people with treatment through PAHO and partner donations, while sustained technical and logistical support to the Ministry of Popular Power for Health (MPPS) has strengthened the national supply chain and ensured the continuity of health services through the coordination, reception, and mobilization of international donations of essential medical products.
AstraZeneca - How is AI helping scientists design the next generation of biologic medicines?
Learn how AstraZeneca combines AI drug discovery, laboratory automation and biology to refine biologic molecules and inform earlier decisions.
Czech PM targets medicine prices in new bid to cut healthcare costs
The pharmaceutical industry warns that medicines already account for a declining share of healthcare spending, arguing that efficiency gains should also be sought in other areas
Health Policy Watch | US finally signs health deal with Zambia, but still pursues minerals agreement
In 2024, 84% of Zambia’s HIV programme was funded by PEPFAR – and 1.3 million Zambians are on antiretroviral medicines.
They Created a Cell That’s Almost Alive. What to Do With It Now?
SpudCells may one day produce new medicines and materials. But first scientists have to improve them — and make sure they aren’t misused.
Modern medicine failed her. She turned to toad venom instead
An increasing number of people are turning to complementary and alternative medicines, and the terms are evolving. Here's what's going on.
GLP-1s: the science behind today’s weight-loss drugs
The medicines reshaping obesity treatment grew out of research into how the body handles a meal. Long before weekly weight-loss injections became familiar, scientists were studying signals that travel from the intestine to the pancreas, helping it release insulin when nutrients arrive.
This is what the 2026 Nobel prize for chemistry is all about
The Nobel prize in chemistry 2026 has been awarded to two scientists, Henri B Kagan at Paris-Sud University in France and Kensō Soai at Tokyo University of Science in Japan. Their discoveries showed how chemical reactions can produce an overwhelming excess of one of two mirror image forms of a molecule. Science journalist Linda Geddes tells Madeleine Finlay how this has become an important tool in drug development, allowing a greater understanding of how medicines work in the body